Sentry Investment Management LLC Grows Holdings in Becton Dickinson and Co (BDX)
Sentry Investment Management LLC boosted its position in shares of Becton Dickinson and Co (NYSE:BDX) by 15.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 20,787 shares of the medical instruments supplier’s stock after purchasing an additional 2,767 shares during the quarter. Sentry Investment Management LLC’s holdings in Becton Dickinson and were worth $4,450,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Legacy Advisors LLC increased its holdings in Becton Dickinson and by 7,000.0% during the 4th quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock worth $106,000 after purchasing an additional 490 shares during the period. FTB Advisors Inc. increased its holdings in shares of Becton Dickinson and by 114.2% in the 4th quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock valued at $116,000 after acquiring an additional 290 shares during the period. Harfst & Associates Inc. increased its holdings in shares of Becton Dickinson and by 46.4% in the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after acquiring an additional 221 shares during the period. Exane Derivatives increased its holdings in shares of Becton Dickinson and by 848.6% in the 4th quarter. Exane Derivatives now owns 702 shares of the medical instruments supplier’s stock valued at $150,000 after acquiring an additional 628 shares during the period. Finally, Meeder Asset Management Inc. purchased a new position in shares of Becton Dickinson and in the 4th quarter valued at $160,000. Institutional investors own 75.56% of the company’s stock.
Shares of Becton Dickinson and Co (BDX) opened at $215.40 on Wednesday. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.54 and a quick ratio of 0.93. The firm has a market capitalization of $58,277.82, a price-to-earnings ratio of 164.43, a PEG ratio of 1.50 and a beta of 1.12. Becton Dickinson and Co has a 52-week low of $175.66 and a 52-week high of $248.39.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 9th will be given a $0.75 dividend. The ex-dividend date is Thursday, March 8th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.39%. Becton Dickinson and’s payout ratio is 229.01%.
A number of research analysts have recently issued reports on the company. Morgan Stanley lifted their price target on Becton Dickinson and from $245.00 to $250.00 and gave the company an “equal weight” rating in a report on Wednesday, February 7th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $260.00 price target (up from $223.00) on shares of Becton Dickinson and in a report on Tuesday, February 6th. Zacks Investment Research upgraded Becton Dickinson and from a “hold” rating to a “buy” rating and set a $240.00 price target on the stock in a report on Wednesday, January 3rd. Evercore ISI assumed coverage on Becton Dickinson and in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $245.00 price target on the stock. Finally, Deutsche Bank set a $260.00 price target on Becton Dickinson and and gave the company a “buy” rating in a report on Friday, December 29th. Four equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $237.27.
In other news, Director Timothy M. Ring sold 269,661 shares of the firm’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $217.82, for a total value of $58,737,559.02. Following the completion of the sale, the director now owns 295,753 shares of the company’s stock, valued at approximately $64,420,918.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.00% of the stock is owned by company insiders.
Becton Dickinson and Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.